AU2002327744A1 - Orally administered liquid compositions comprising guaifenesin and a polyoxyalkylene block copolymer - Google Patents
Orally administered liquid compositions comprising guaifenesin and a polyoxyalkylene block copolymerInfo
- Publication number
- AU2002327744A1 AU2002327744A1 AU2002327744A AU2002327744A AU2002327744A1 AU 2002327744 A1 AU2002327744 A1 AU 2002327744A1 AU 2002327744 A AU2002327744 A AU 2002327744A AU 2002327744 A AU2002327744 A AU 2002327744A AU 2002327744 A1 AU2002327744 A1 AU 2002327744A1
- Authority
- AU
- Australia
- Prior art keywords
- composition
- add
- water
- block copolymer
- mix
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Description
ORALLY ADMINISTERED LIQUID COMPOSITIONS COMPRISING GUAIFENESIN AND A POLYOXYA KYLENE BLOCK COPOLYMER
TECHNICAL FIELD
The present invention is in the field orally administered liquid compositions for delivering pharmaceutical actives to humans and animals.
BACKGROUND
Pharmaceutical actives are generally delivered using dosage forms designed to promote ease in using while encouraging maximum efficacy of the active. Among the challenges regarding creating dosage forms taken by mouth is formulating such a product in a form small enough to be easily swallowed.
When the desired dosage form is a liquid, then the pharmaceutical actives or actives must be solubilized in a vehicle wherein the composition is easy to use and maximizes therapeutic effectiveness. One such composition is a pharmaceutical suspension. A suspension is where solid active particles are dispersed within a liquid vehicle. Although suspensions are a very useful way to concentrate an active in a small volume, they possess some inherent disadvantages. One disadvantage is that over time the active particles settle to the bottom or float to the top of the liquid, resulting in a suspension that is not homogenous. Thus, a patient who uses a suspension in such a condition is likely to receive more or less active than the intended dose. In some cases this could result in a consumer taking a high and potentially a hazardous dose or conversely, a dose that lacks the minimum level of active required to provide the intended therapeutic benefit. Another disadvantage of suspensions relates to absoφtion of the active. For absoφtion to take place, a pharmaceutical active must first be in a solubilized state. Thus, suspensions that contain actives not previously solubilized must undergo dissolution in bodily fluids prior to absoφtion. Such a dissolution step may slow down the onset of the desired therapeutic effect.
In light of the disadvantages of suspensions mentioned above, those skilled in the art have created solutions in the form of elixirs and syrups for delivery of actives. These solutions can be easily and conveniently swallowed in 5, 10 or even 50 ml volumes. In certain cases, however, it is desirable to deliver the active in a true solution that is in a small volume of less
than about 3 ml, even less than 1 ml. Up to now, achieving such small volumes has been problematic and for some actives nearly impossible. The problem is exacerbated where the dose level of the active is required to be large, or wherein the active agent is especially insoluble in the usual vehicles used for pharmaceuticals.
Liquid-filled, soft gelatin capsules were developed in response to this challenge. There are, however, limits to using such capsules. One limitation is when the requisite level of actives cannot be contained in a small volume. Liquid-centered, soft gelatin capsules containing acetaminophen has been the subject of a great deal of effort in order to solve problems such as those mentioned above. For example, in U.S. Patent 5,505,961, assigned to R.P. Scherer reputes to have solved such problems associated with soft gelatin capsules, particularly where high dose levels of acetaminophen is required to provide therapeutic benefits. It is disclosed therein that acetaminophen, with or without other actives, is soluble in solvents including polyethylene glycol, water, propylene glycol, a solubilizing agent including potassium (or sodium) acetate and polyvinylpyrrolidone or PVP. It is disclosed therein, PVP is essential for inhibiting crystallization in such compositions. PCT Application WO93/00072, Coapman, discloses a process for solubilizing pharmaceutical actives considered difficult to solubilize. This process requires PVP to aid in solubilizing the active agent and preventing precipitation. Similar limitation are disclosed for the acetaminophen solutions described in PCT Application WO95/23595, by Dhabhar, wherein PVP is disclosed as an essential component of the compositions that are the subject matter of the patent.
PVP is a high molecular weight polymer that while inhibiting crystallization, also is responsible for increasing compositional viscosity of the liquid compositions. Such a viscosity increase is not significant for products contained in capsules intended for swallowing. The high viscosity associated with such liquid compositions containing PVP, however, does inhibit effective oral dosing of low volume products particularly from exact dosing implements such as medicine droppers, oral syringes, dosing cups and sachets. High viscosity liquid compositions are an impediment to being easily dosed from these types of exact dosing implements and do not spread easily over large surface areas of oral mucosal tissue.
When avoiding PVP and its related problems, new problems associated with oral dosing can develop. For example, U.S. Patent 5,360,615, assigned to R.P. Scherer, discloses solubilizing the active by adding acid or base to cause the partial ionization of the active. It has been found, however, that this approach is undesirable in the case of liquid solutions to be delivered into the
mouth for absoφtion through mucosal membranes since the active's ionization inhibits such absoφtion.
One very important consideration in choosing a product form, therefore, is determining the active's intended delivery site within the body. The prior art describing medicaments to be delivered to the stomach include liquid-center gelatin capsules. The liquids contained in these capsules are not intended to contact the body until the gelatin shell dissolves in the stomach. In such a product it is superfluous whether the liquid in the gelatin is highly viscous, or even a paste or solid. For administration into the mouth, however, the composition's ability to flow is critical. Low viscosity liquids permit accurate administration from current or developing exacting dispensing or dosing devices for administering a liquid composition to a person. Low viscosity liquids are easier to swallow and make the composition acceptably palatable. Such consumer acceptance is very important for encouraging consumers to comply with dosing instructions to receive the intended therapeutic benefit. Aside from the aesthetic considerations, it's desired that the formulation spread over a large surface area of mucosal tissue to enhance the diffusion of the respective actives within the formulation through the mucosal membranes.
SUMMARY OF THE INVENTION
The inventors here have worked to create compositions comprising pharmaceutical actives normally difficult to solubilize in high concentration for delivery into the mouth. The fundamental relationship between the pharmaceutical actives and the vehicles into which they are incoφorated is that the actives are maintained in solution while the in-use character of the composition is flowable as well as a pourable for enhancing the delivery of the pharmaceutical actives to the oral cavity.
After diligent research in trying to obtain such compositions, the inventors have suφrisingly discovered that there is an important relationship of the components comprising the vehicle for solubilizing the active. When the components of the vehicle are in the particular levels and ratios to one another as shown in Figure 1, the pharmaceutical actives remain in solution and are pourable and flowable at temperatures other than ambient temperature such as body temperature.
The present invention, therefore, is an orally administered liquid pharmaceutical composition that demonstrates excellent physical stability while delivering concentrated levels of the pharmaceutical active(s). Specifically, these compositions do not exhibit active precipitation
from the solution for extended periods. Other advantages of this invention include uniform and correct dosing to patients. Additionally, the compositions remain liquid in the oral cavity thereby exposing large surface areas of oral mucosal tissue to the pharmaceutical actives intended to pass through that oral mucosal tissue. As a result, the compositions are efficacious and patient- preferable due to their improved palatability. The formulations also permit the solubilization of both lipophilic active agents, and hydrophilic excipients and formulation aids at the same time.
BRIEF DESCRIPTION OF THE FIGURES
FIGS 1 illustrates a ternary mixture diagram that is a graphical representation of three varying relationships of the three primary components of the vehicle of compositions of the present invention. The axes of the diagram correspond to these three components.
DEFINITIONS Terms useful herein are defined below. Additionally, terms used in the art, as well as general concepts, are further described in Schramm, The Language of Colloid and Interface Science. American Chemical Society, (1993), incoφorated herein by reference:
"Hydrophilic solvents" are used herein to describe polar, pharmaceutically acceptable solvents that are miscible with water and possess a dielectric constant (ε) of approximately 20 or greater as found in Martin's Physical Pharmacy, Fourth Edition, Pages 213-214.
"Low volume dose" as used herein means doses of a liquid composition less than about 3 mis wherein the pharmaceutical active is sufficiently concentrated to produce the desired therapeutic response upon oral administration.
"Optical density" or "OD" is a measurement of the absoφtion of radiation by a mixture of ingredients forming a liquid or a layer of said liquid. The OD is expressed mathematically as the negative common logarithm of the transmittance of light (T) by the mixture. Optical density value is measured using the equation, OD = loglO (1/T).
"Orally administered" as used herein means the composition is introduced into the oral cavity making contact with the tissues inside the oral cavity prior to it being swallowed or ingested.
"Physical stability" as used in the context of the present composition means the composition's resistance to changes in the number and relative amounts of phases of matter present.
"Pourable" as used herein means the ability of a liquid to remain in a highly flowable state regardless of the exposure of said liquid to temperatures from about 15°C to about 40°C at normal atmospheric pressure.
"Solution" as used herein means a uniform dispersed mixture at molecular or ionic level of one or more pharmaceutical actives (the solute) in one or more other substances (the solvent). The physical state of the solution at normal ambient conditions is such that it is readily dispensed from a vessel by pouring.
DETAILED DESCRIPTION OF THE INVENTION
The present invention is an orally administered liquid pharmaceutical composition having excellent physical stability while containing concentrated levels of pharmaceutical actives. In addition to these pharmaceutical actives, these compositions comprise a vehicle for solubilizing the actives wherein the vehicle comprises hydrophilic solvents, polyoxyalkylene block copolymers and water together in levels and ratios to one another wherein the actives are solubilized and remain as such over extended periods of time. Hydrophilic solvents and water also facilitate the incoφoration of other compounds, such as sweetening agents and stabilizers, into the composition of the present invention. Compositions of the present invention provide accurate delivery of the active, particularly when the composition is packaged in exacting dose measuring devices including graduated tubes, droppers, pipettes, single or unit dose liquid elixir packages, atomizers, liquid filled edible capsules or drops or other such packages. In addition, these solutions readily spread over large surface areas of the mucosal tissues in the oral cavity, throat, oropharynx and combinations thereof, resulting in some actives being rapidly absorbed.
Consumers show strong preference for lower dose volumes that contain a sufficiently high enough concentration of pharmaceutical actives to provide the desired therapeutic benefit of the active. As a result of this effort to meet consumer needs, the compositions of the present invention are intended to be dosed in low volumes. In the present invention it is envisioned that the maximum volume of a single dose of the compositions of the present invention is no greater that about 3 ml, alternatively no greater than 2.5 ml.
All percentages of the components comprising the invention are herein referred to by their weight of the composition.
Pharmaceutical Actives:
The pharmaceutical actives of the present invention are those that are particularly difficult to solubilize in a small volumes of solvents since the actives are already close to their solubility limit. At such concentrations these pharmaceutical actives tend to be physically unstable, precipitating out of solution when the composition is subject to minor changes in ambient temperature, level of contaminates in the solution or other commonly known factors that precipitate an active from a solution. Precipitation can take place at any point from just after manufacture and packaging of the compositions, through its normally expected shelf life.
The compositions of the present invention contain pharmaceutical actives that are soluble in the polyoxyalkylene block copolymers, hydrophilic solvents and water that comprise the vehicle of the composition of the present invention. The pharmaceutical actives include guaifenesin alone or in combination other actives selected from the group of antihistamines, antitussives, expectorants/mucolytics, bronchodilators, decongestants and mixtures thereof.
Guaifenesin is known for symptomatic relief of respiratory conditions characterised by dry, non-productive cough and presence of mucus in the respiratory tract. The action of guaifenesin ameliorates dry unproductive cough by decreasing sputum viscosity and difficulty in expectoration and increasing sputum volume. (Ref. Remington The Science and Practice of Pharmacy, 20 Third Ed., p.1303, published by Philadelphia College of Pharmacy and Sciences; herein incoφorated by reference). Additionally, it is indicated as a fertility aid in women by thinning mucous endogenous to the reproductive tract.
There are a host of actives that may be combined with guaifenesin. These actives are from suitable classes of agents including, but not limited to the following:
Antihistamines: including, hydroxyzine, pyrilamine, phenindamine, dexchloφheniramine, clemastine diphenhydramine, azelastine, acrivastine, levocarbastine, mequitazine, astemizole, ebastine, loratadine, cetirizine, terfenadine, promethazine, dimenhydrinate, meclizine, tripelennamine, carbinoxamine, cyproheptadine, azatadine, brompheniramine, triprolidine, cyclizine, thonzylamine, pheniramine, and mixtures thereof.
Antitussives: including, hydrocodone, noscapine, benzonatate, diphenhydramine, chlophedianol, clobutinol, fominoben, glaucine, pholcodine, zipeprol, hydromoφhone, carbetapentane, caramiphen, levopropoxyphene, codeine, dextromethoφhan, pholcodine and mixtures thereof.
Expectorants/Mucolvtics : including, ambroxol, bromhexine, teφin, potassium iodide, n- acetylcysteine, and mixtures thereof.
Bronchodilators: preferably for inhalation, including, albuterol, epinephrine, ephedrine, metaproterenol, terbutaline, theophylline, ammphylline isoetharine, terbutaline, isoetharine, pirbuterol, bitolterol, fenoterol, rimeterol, ipratroprium, and mixtures thereof.
Decongestants: including pseudoephedrine, phenylephrine, phenylpropanolamine and their salts and mixtures thereof.
The level of pharmaceutical actives in the compositions of the present invention is from about 2% to about 40%, alternatively 3% to 40 %, and also 5% to 30% of the composition. The level of each active making up the aggregate or combination of the pharmaceutical actives is determinable by one skilled in the art when considering factors including the physicochemical and bioavailability characteristics of the active, the dose regime and the age, weight and physical condition of the patient as well as the stability of the system that incoφorates these actives. In regard to this last point, the inventors spent significant effort in working within the confines of present composition's components to determine whether such a system will remains physically stable.
Vehicle
In addition to the actives discussed above, the composition of the present invention comprises a vehicle. The level of the vehicle can be 100% of the composition minus the active and optional ingredients as discussed below. In the present invention, the level of the vehicle in the composition is typically from about 40% to about 98%, alternatively from about 60% to about 90%. The vehicle of the present inventions comprises a three-component mixture of (a) polyoxyalkylene block copolymers, (b) hydrophilic solvents and (c) water, wherein these three components are present in specific proportions to each other. The specific proportions are most readily represented using the ternary (or 3 component) mixture diagram. Such diagrams are well known in the art to described such mixtures; see "Experiments with Mixtures", John A. Cornell, 1990, John Wiley and Sons, New York, pp. 2-8; herein incoφorated by reference. In the case of such mixtures, the total amount of the three components present represents 100% of the vehicle and each component is a proportion of that total amount. The vehicle of the compositions of the present invention may be described precisely using the three-component mixture diagram referred to here as FIG 1. The vehicle is defined as region 1 of FIG 1, bounded
by the lines connecting the vertices of the parallelogram A, B, C and D or segment lines AB, BC, CD and DA.
These vertices are located on the diagram wherein the polyoxyalkylene block copolymer proportions of the is 5% and 25% of the vehicle, hydrophilic solvent portion at 30, 50, 70 and 90% of the vehicle, and water at a portion of 5% and 45% of the vehicle. The vertices of the parallelogram are found at the following 4 points:
In determining the percentages of each component comprising the vehicle, the components cannot be varied independently of each other. The proportion of one component depends on the proportion of the other two. For example, if the water proportion falls within the range of 5 - 45% and the polyoxyalkylene block copolymer falls within the range of 5 - 25%, the hydrophilic solvent range is determined using the following equation:
100% - (% polyoxyalkylene block copolymer + % water); In this example, the range is calculated to be from about 30% to about 90%.
Polyoxyalkylene block copolymers, also herein referred to as "poloxamers", are nonionic block copolymers of ethylene oxide and propylene oxide corresponding to the following structure:
CH3 I HO— (CH2CH2O)x- - (CH2CHO)y- - - (CH2CH2O)χ. — H
The polyoxyalkylene block copolymers useful in the present invention include those wherein x has a value from about 1 to about 130, y has a value from about 1 to about 72 and x has a value from about 0 to about 130, wherein the average molecular weight of said copolymer is from about 3000 to about 15,000. Alternatively, the polyoxyalkylene block copolymers of the present invention are those where x equals 100, y equals 70 and x' equals 100 and has an average molecular weight of about 12,600 alternatively where x equals 76, y equals 31 and x' equals 76
and has an average molecular weight of 8400. The vehicle of the present invention comprises from about 5% to about 25% and alternatively from about 5% to about 20% poloxamer.
The poly (oxyethylene) segment is hydrophilic and the poly (oxypropylene) segment is hydrophobic. Families of poloxamers are available and vary in the number of blocks, the overall average molecular weight, and in the percentage of the molecule which is hydrophilic. A block refers to a single polyoxyethylene or polyoxypropylene segment. Di-block and tri-block polymers have been described. In the case of tri-block copolymers, the blocks can be arranged in the format of one polyoxypropylene block surrounded by 2 polyoxyethylene blocks, that being the most common poloxamer structure, or alternatively as one polyoxyethylene block surrounded by 2 polyoxypropylene blocks, the latter sometimes referred to as a reverse poloxamer. Poloxamers are available under the trade names of Lutrol®, Monolan®, or Pluronic®. The chemical structure, synthesis, and properties have been described as [poly (ethylene oxide)/poly (propylene oxide)] block copolymer surfactants by Paschalis Alexandridis, Current Opinions in Colloid and Interface Science. Vol. 2, pp. 478-489 (1997); herein incoφorated by reference.
For health care applications preferable poloxamers include Pluronic® F127, Pluronic® LI 220, and Pluronic® F68. These specific polymers are available from BASF Coφoration.
In the present invention it is envisioned that combining hydrophilic solvents with the poloxamers and water provides an environment suitable for solubilizing pharmaceutical actives wherein the composition demonstrates the previously discussed physical stability. The vehicle of the present invention comprises from about 30% to about 90%, alternatively from about from about 35% to about 90% and finally from about 40% to about 90% hydrophilic solvents.
The hydrophilic solvents of specific interest are selected from the group consisting of monohydric and polyhydric alcohols. The preferable monohydric alcohols of the present invention include ethanol and tetraglycol. Absolute ethanol is available from Aaper Alcohol & Chemical Co., Shelbyville, KY. Polyhydric alcohols of the present invention are selected from the group consisting of glycols, monosaccharides, oligosaccharides and mixtures thereof. Glycols are particularly useful as the hydrophilic solvent of the present invention. Glycols used in the present invention are selected from the group consisting of glycerin, propylene glycol and polyethylene glycol. The monosaccharides of the present invention are selected from the group consisting glyceraldehydes, ribose, glucose, fructose, invert sugars (such as honey) and mixtures thereof. The oligosaccharides of the present invention are selected from the group consisting of maltose, sucrose, raffinose, lactose, cellobiose, ribose, sorbitol, mannitol, xylitol, inositol, galactose, mannose, xylose, rhamnose, glutaraldehyde and mixtures thereof.
In addition to the components previously discussed, the present invention comprises water. The level of water in the vehicle of the present invention is from about 5% to about 45%, alternatively from about 5% to about 40%.
Optional Ingredients
The composition can include optional ingredients traditionally included in orally administered liquid compositions, typically to improve the aesthetics of the composition. These optional ingredients include, but are not limited to, dyes, fragrances, preservatives, antioxidants, and similar types of compounds. Specific optional ingredients include, but, are not restricted to surfactants including tyloxapol, polysorbate 80, lauroglycol 90, polyox 40 stearate, capryol 90, polymers including polyvinylpyrrolidone, hydroxypropyl methyl cellulose, beta-cyclodextrins, or solvents, such as propylene carbonate, n-methylpyrrolidone, transcutol, dimethylisosorbide and mixtures thereof. These optional ingredients are included in the composition in an amount sufficient to perform their intended function without compromising the benefits associated with the present invention.
METHODS
Methods for Treating Illness
The delivery of drugs into the bloodstream by placing a dosage form into the mouth can be classified into two major subclasses dependant upon the desired action. In one case where the drug is delivered into the blood by absoφtion after swallowing (i.e. from the stomach, small intestine or colon) and in the other case where absoφtion, or at least the significant amount of the absoφtion occurs through the membranes of the oral cavity either immediately or over extended periods of time when the compositions are retained in the mouth prior to swallowing. This route is generally referred to as "buccal" or "oral mucosal" absoφtion versus the former route normally referred to as peroral administration of actives. Peroral administration of actives is by far the most commonly used in all of medicine, has been well studied, and is explained in detail in: Mayerson, M., Principles of Drug Absoφtion; Chapter 2 in "Modern Pharmaceutics", 2nd ed., G.S. Banker and C.T. Rhodes, editors, Marcel Dekker Inc., New York, 1990; herein incoφorated by reference.
In terms of the methods of delivery of the active, it is generally accepted that oral mucosal delivery inside the mouth is targeted to the sub-lingual region to achieve rapid therapeutic effects; see D. Harris and J.R. Robinson, Drug Deliverv via the Mucus Membranes of
the Oral Cavity. Journal of Pharmaceutical Sciences 81: 1, 1992. Such dosage forms are delivered under the tongue, on the floor of the mouth, and held there for some extended time. The inventors have found, however, that a large increase in bioavailability with very rapid absoφtion can be achieved for particular pharmaceutical actives when the subject compositions are placed against any of the mucosal membranes of the mouth, throat, tongue, oropharynx and combinations thereof and swallowed; see PCT Publication 00/41693, Dobrozsi et al., published July 20, 2000; herein incoφorated by references.
The form of the invention is a liquid or an elixir intended to be applied to any of the mucosal membranes within the mouth. This can be achieved using a medicine dropper that is calibrated to indicate the proper amount to be administered, and squirting the elixir onto the tongue prior to swallowing. The elixir can be atomized into mouth and throat and then swallowed. It can be encapsulated into some sort of edible and, or chewable shell that makes it portable and convenient to transport and administer without having to measure the quantity of liquid elixir. Examples of encapsulation shells include hard candies as are used for lozenges, gelatin and starch-based shells and combination thereof. The elixir may be packaged into single dose, small, disposable vials easily opened wherein the elixir is squirted or poured into the mouth. Typical dosage forms of the composition of the present invention contain no more than about 3 ml., alternatively from about 0.2 ml. to about 3ml.
Method for Characterizing the Physical Stability of the Present Invention
Susceptibility of changes in moφhology and appearance of a composition is indicative of the composition's physical stability. Among the tests to measure this stability is that of measuring the liquid's optical density. This method is thermo-chemical, wherein samples of the compositions and control samples are prepared by the methods as disclosed in the examples below, and packed in 30 ml amber glass bottles leaving a minimal headspace. The bottles were placed in a thermally insulated chamber at a constant temperature of less than 5°C until being pulled for testing. The OD of the samples including controls and samples of the present invention are evaluated for physical stability by measuring the optical density of each sample. The test is made using a spectrophotometer such as a Jenway Model 6405 UV/VIS, set at a transmittance wavelength of 530 nm. Physical stability is a function of the composition's transmittance of light. The light transmittance of the composition is directly related to the liquids turbidity, sedimentation/precipitation and, or content of crystals found in the liquid.
Measurements of the samples are made at intervals of 7 days. The values are averaged over the entire testing period of 3 months. A formulation with lower optical density values is
proposed as having greater overall physical stability. It is required for the composition of the present invention to have Optical Density (OD) value less or equal to 0.05, indicating good physical stability of the composition.
EXAMPLES Example 1: Composition for the Treatment of Cough with an Expectorant
Pluronic F 127 is available from BASF Specialty Chemicals, Mt. Olive, NJ.
Preparation:
Add propylene glycol and poloxamer to a clean vessel (main mix). While stirring, heat the mixture as appropriate to sufficiently melt the poloxamer. Add Guaifenesin and continue stirring. Once a uniform solution is obtained remove from heat source and continue mixing. In a separate vessel (alcohol pre-mix) add alcohol, dextromethoφhan base and monoammonium glycyrrizinate and mix until uniform. In another vessel (water pre-mix), add water, EDTA, sodium saccharin, acesulfame, sucralose and sodium metabisulfite. Mix until all materials are dissolved.
Add the alcohol containing premix to the main mixing vessel containing the poloxamer. Mix until uniform. While stirring, add the water containing premix to the main
vessel and continue to mix until uniform Subsequently, add desired flavor component and mix until uniform.
Example 2: Composition for the Treatment of Cough with an Expectorant
Pluronic F 127 is available from BASF Specialty Chemicals, Mt. Olive, NJ.
Preparation:
Add propylene glycol, tyloxapol and poloxamer to a clean vessel (main mix). While stirring, heat the mixture as appropriate to sufficiently melt the poloxamer. Add Guaifenesin and continue stirring. Once a uniform solution is obtained remove from heat source and continue mixing. In a separate vessel (alcohol pre-mix) add alcohol, dextromethoφhan base, transcutol and monoammonium glycyrrhizinate and mix until uniform. In another vessel (water pre-mix), add water, EDTA, sodium saccharin, acesulfame, sucralose and sodium metabisulfite. Mix until all materials are dissolved.
Add the alcohol containing premix to the main mixing vessel containing the poloxamer. Mix until uniform. While stirring, add the water containing premix to the main
vessel and continue to mix until uniform. Subsequently, desired flavor component and mix until uniform.
Example 3 : Composition for the Treatment of Cough with an Expectorant
Pluronic F68 is available from BASF Specialty Chemicals, Mt. Olive, NJ.
Preparation:
Add propylene glycol and poloxamer to a clean vessel (main mix). While stirring, heat the mixture as appropriate to sufficiently melt the poloxamer. Add Guaifenesin and continue stirring. Once a uniform solution is obtained remove from heat source and continue mixing. In a separate vessel (alcohol pre-mix) add alcohol, dextromethoφhan base and mix until uniform. In another vessel (water pre-mix), add water, EDTA, sodium saccharin, acesulfame, sucralose and sodium metabisulfite. Mix until all materials are dissolved.
Add the water containing premix to the main mixing vessel containing the poloxamer. Mix until uniform. While stirring cool and add the alcohol containing premix to the main vessel and continue to mix until uniform Subsequently, add desired flavor component and mix until uniform.
Example 4: Composition for the Treatment of Cough with an Expectorant
'Pluronic® F 127 is available from BASF Specialty Chemicals, Mt. Olive, NJ.
Preparation:
Add propylene glycol, tyloxapol and poloxamer to a clean vessel (main mix). While stirring, heat the mixture as appropriate to sufficiently melt the poloxamer. Add Guaifenesin and continue stirring. Once a uniform solution is obtained remove from heat source and continue mixing. In a separate vessel (alcohol pre-mix) add alcohol, dextromethoφhan base, and monoammonium glycyrrizinate and mix until uniform. In another vessel (water pre-mix), add water, EDTA, sodium saccharin, acesulfame, sucralose and sodium metabisulfite. Mix until all materials are dissolved.
Add the alcohol containing premix to the main mixing vessel containing the poloxamer. Mix until uniform. While stirring, add the water containing premix to the main vessel and continue to mix until uniform. Subsequently, desired flavor component and mix until uniform.
Example 5: Composition for the Treatment of Cough with an Expectorant
•Pluronic® F 127 is available from BASF Specialty Chemicals, Mt. Olive, NJ.
Preparation:
Add propylene glycol and poloxamer to a clean vessel (main mix). While stirring, heat the mixture as appropriate to sufficiently melt the poloxamer. Add Guaifenesin and continue stirring. Once a uniform solution is obtained remove from heat source and continue mixing. In a separate vessel (alcohol pre-mix) add alcohol, dextromethoφhan base, transcutol and monoammonium glycyrrizinate and mix until uniform. In another vessel (water pre-mix), add water, EDTA, sodium saccharin, acesulfame, sucralose and sodium metabisulfite. Mix until all materials are dissolved.
Add the alcohol containing premix to the main mixing vessel containing the poloxamer. Mix until uniform. While stirring, add the water containing premix to the main vessel and continue to mix until uniform. Subsequently, desired flavor component and mix until uniform.
Example 6: Composition for the Treatment of Cough with an Expectorant
luronic® LI 220 is available from BASF Specialty Chemicals, Mt. Olive, NJ.
Preparation:
Add propylene glycol and poloxamer to a clean vessel (main mix). While stirring, heat the mixture as appropriate to sufficiently dissolve the poloxamer. Add Guaifenesin and continue stirring. Once a uniform solution is obtained remove from heat source and continue mixing. In a separate vessel (alcohol pre-mix) add alcohol, dextromethoφhan base, and mix until uniform. In another vessel (water pre-mix), add water, EDTA, sodium saccharin, acesulfame, sucralose and sodium metabisulfite. Mix until all materials are dissolved.
Add the water containing premix to the main mixing vessel containing the poloxamer. Mix until uniform. While stirring cool and add the alcohol containing premix to the main vessel and continue to mix until uniform Subsequently, add desired flavor component and mix until uniform.
Example 7: Composition for the Treatment of Cough with an Expectorant
Tluronic® F 127 is available from BASF Specialty Chemicals, Mt. Olive, NJ.
Preparation:
Add propylene glycol and poloxamer to a clean vessel (main mix). While stirring, heat the mixture as appropriate to sufficiently melt the poloxamer. Add Guaifenesin and continue stirring. Once a uniform solution is obtained remove from heat source and continue mixing. In a separate vessel (alcohol pre-mix) add alcohol, dextromethoφhan base, transcutol and mix until uniform. In another vessel (water pre-mix), add water, EDTA, sodium saccharin, acesulfame, sucralose and sodium metabisulfite. Mix until all materials are dissolved.
Add the alcohol containing premix to the main mixing vessel containing the poloxamer. Mix until uniform. While stirring, add the water containing premix to the main vessel and continue to mix until uniform. Subsequently, desired flavor component and mix until uniform.
Example 8: Composition for the Treatment of Cough with an Expectorant
Pluronic® F127 is available from BASF Specialty Chemicals, Mt. Olive, NJ.
Preparation:
Add propylene glycol, tetraglycol and poloxamer to a clean vessel (main mix). While stirring, heat the mixture as appropriate to sufficiently melt the poloxamer. Add Guaifenesin and continue stirring. Once a uniform solution is obtained remove from heat source and continue mixing. In a separate vessel (alcohol pre-mix) add alcohol, dextromethoφhan base and mix until uniform. In another vessel (water pre-mix), add water, EDTA, sodium saccharin, acesulfame, sucralose and sodium metabisulfite. Mix until all materials are dissolved.
Add the alcohol containing premix to the main mixing vessel containing the poloxamer. Mix until uniform. While stirring, add the water containing premix to the main vessel and continue to mix until uniform. Subsequently, desired flavor component and mix until uniform.
Example 9: Composition for the Treatment of Cough with an Expectorant
Pluronic F68 is available from BASF Specialty Chemicals, Mt. Olive, NJ.
Preparation:
Add propylene glycol and poloxamer to a clean vessel (main mix). While stirring, heat the mixture as appropriate to sufficiently melt the poloxamer. Add Guaifenesin and continue stirring. Once a uniform solution is obtained remove from heat source and continue mixing. In a separate vessel (alcohol pre-mix) add alcohol, dextromethoφhan base and mix until uniform. In another vessel (water pre-mix), add water, EDTA, sodium saccharin, acesulfame, sucralose and sodium metabisulfite. Mix until all materials are dissolved.
Add the alcohol containing premix to the main mixing vessel containing the poloxamer. Mix until uniform. While stirring, add the water containing premix to the main vessel and continue to mix until uniform Subsequently, add desired flavor component and mix until uniform.
Example 10: Composition for the Treatment of Cough with an Expectorant
luronic® F 127 is available from BASF Specialty Chemicals, Mt. Olive, NJ.
Preparation:
Add propylene glycol, tetraglycol and poloxamer to a clean vessel (main mix). While stirring, heat the mixture as appropriate to sufficiently melt the poloxamer. Add Guaifenesin and continue stirring. Once a uniform solution is obtained remove from heat source and continue mixing. In a separate vessel (alcohol pre-mix) add alcohol, dextromethoφhan base, and transcutol and mix until uniform. In another vessel (water pre-mix), add water, EDTA, sodium saccharin, acesulfame, sucralose and sodium metabisulfite. Mix until all materials are dissolved.
Add the alcohol containing premix to the main mixing vessel containing the poloxamer. Mix until uniform. While stirring, add the water containing premix to the main vessel and continue to mix until uniform. Subsequently, desired flavor component and mix until uniform.
Example 11 : Composition for the Treatment of Bronchitis with an Expectorant
Pluronic F 127 is available from BASF Specialty Chemicals, Mt. Olive, NJ.
Preparation:
Add propylene glycol and poloxamer to a clean vessel (main mix). While stirring, heat the mixture as appropriate to sufficiently melt the poloxamer. While stirring add guaifenesin and ambroxol. Once a uniform solution is obtained remove from heat source and continue mixing. Finally, add alcohol and water to the vessel and mix until uniform.
•Pluronic® LI 220 is available from BASF Specialty Chemicals, Mt. Olive, NJ.
Preparation:
Add propylene glycol, and poloxamer to a clean vessel (main mix). While stirring, heat the mixture as appropriate to sufficiently melt the poloxamer. Add guaifenesin continue stirring. Once a uniform solution is obtained remove from heat source and continue mixing. In a separate vessel (alcohol pre-mix) add alcohol, dextromethoφhan base and mix until uniform. In another vessel (water pre-mix), add water, EDTA, sodium saccharin, acesulfame, sucralose and sodium metabisulfite. Mix until all materials are dissolved.
Add the alcohol containing premix to the main mixing vessel containing the poloxamer. Mix until uniform. While stirring, add the water containing premix to the main vessel and continue to mix until uniform. Subsequently add the desired flavor component and mix until uniform. Make individual filled lozenges containing about 1.0 ml. of liquid per lozenge by a commonly used method such as extrusion.
Pluronic F 127 is available from BASF Specialty Chemicals, Mt. Olive, NJ.
Preparation:
Add propylene glycol, and poloxamer to a clean vessel (main mix). While stirring, heat the mixture as appropriate to sufficiently melt and dissolve the poloxamer. Add guaifenesin continue stirring. Once a uniform solution is obtained remove from heat source and continue mixing. In a separate vessel (alcohol pre-mix) add alcohol and dextromethoφhan base and mix until uniform. In another vessel (water pre-mix), add water, EDTA, sodium saccharin, acesulfame, sucralose and sodium metabisulfite. Mix until all materials are dissolved.
Add the alcohol containing premix to the main mixing vessel containing the poloxamer. Mix until uniform. While stirring, add the water containing premix to the main vessel and continue to mix until uniform. Subsequently, desired flavor component and mix until uniform. Make individual filled soft gelatin capsules containing about 1.0 ml. of liquid
Example 14: Composition for the Treatment of Sinusitis or Symptoms of Allergic Rhinitis
Tluronic18 F 127 is available from BASF Specialty Chemicals, Mt. Olive, NJ.
Preparation:
Add propylene glycol and poloxamer to a clean vessel (main mix). While stirring, heat the mixture as appropriate to sufficiently melt the poloxamer. While stirring add guaifenesin and bromhexine. Once a uniform solution is obtained remove from heat source and continue mixing. Finally, add alcohol and water to the vessel and mix until uniform.
Example 15: Composition for the Treatment of Bronchitis with Expectorant
Pluronic F 127 is available from BASF Specialty Chemicals, Mt. Olive, NJ.
Preparation:
Add propylene glycol and poloxamer to a clean vessel (main mix). While stirring, heat the mixture as appropriate to sufficiently melt the poloxamer. While stirring add guaifenesin, bromhexine and ambroxol. Once a uniform solution is obtained remove from heat source and continue mixing. Finally, add alcohol and water to the vessel and mix until uniform.
Example 16: Composition for the Treatment of Infertility
luronic® F 127 is available from BASF Specialty Chemicals, Mt. Olive, NJ.
Preparation:
Add propylene glycol, tetraglycol and poloxamer to a clean vessel (main mix). While stirring, heat the mixture as appropriate to sufficiently melt the poloxamer. Add Guaifenesin and continue stirring. Once a uniform solution is obtained remove from heat source and continue mixing. Add alcohol and continue mixing. In another vessel (water pre-mix), add water, EDTA, sodium saccharin, sucralose and sodium metabisulfite. Mix until all materials are dissolved.
Add the alcohol containing premix to the main mixing vessel containing the poloxamer mix until uniform. While stirring, add the water containing premix to the main vessel and continue to mix until uniform. Subsequently, desired flavor component and mix until uniform.
Claims (10)
1. An orally administered liquid composition comprising from 2% to 40% guaifenesin and a vehicle comprising: a. from 5% to 25% of a polyoxyalkylene block copolymer wherein said polyoxyalkylene block copolymer corresponds to the formula:
CH3 I J HO— (CH2CH2O)x -(CH2CHO)- - - (CH2CH2O)χ.-H x has a value from 1 to 130, y has a value from 1 to 72 and x has a value from 0 to 130; b. from 30% to 90% of a hydrophilic solvent; and c . from 5 % to 45 % water; wherein the proportions of polyoxyalkylene block copolymer, hydrophilic solvent and water are such that the vehicle is in the region bounded by segment lines AB, BC, CD and DA of FIG 1.
2. The orally administered composition according to claim 1 wherein said polyoxyalkylene block copolymer is at a level of 5% to 25%, hydrophilic solvent is at a level from 35% to 90% and wherein said water is at a level from 5% to 40% of said vehicle.
3. The orally administered composition according to claims 1 or 2 wherein said hydrophilic solvent is selected from the group consisting of monohydric and polyhydric alcohols, wherein said polyhydric alcohols are selected from the group consisting of glycols, monosaccharides, oligosaccharides, and mixtures thereof.
4. The orally administered composition according to any one of the preceding claims wherein the hydrophilic solvent is a glycol selected from the group consisting of glycerin, propylene glycol, polyethylene glycol, and mixtures thereof.
5. A method for treating respiratory illnesses using the composition of claim 1 wherein the method comprises oral administration of said composition having a total dosage volume equal to or less than 3.0 ml.
6. The method according to claim 5 wherein the composition is placed against any of the mucosal membranes of the mouth, throat, tongue, oropharynx, and combinations thereof.
7. An orally administered liquid composition comprising from 5% to 30% guaifenesin and a vehicle comprising: a. from 5% to 20% of a polyoxyalkylene block copolymer wherein said polyoxyalkylene block copolymer corresponds to the formula:
CH3 I HO— (CH2CH2O)x- -(CH2CHO)- - - (CH2CH2O)x ~H x equals 100, y equals 70 and x' equals 100 and has an average molecular weight of 12,600; c. from 40% to 90% propylene glycol and ethanol hydrophilic solvent; and d. from 5% to 40% water; wherein the proportions of polyoxyalkylene block copolymer, hydrophilic solvent and water are such that the vehicle is in the region bounded by segment lines AB, BC, CD and DA of FIG 1.
8. A composition according to claim 7 additionally comprising ambroxyl, bromhexine, dextromethoφhan, or combinations thereof.
9. A method for treating respiratory illnesses using the composition of claim 7 wherein the method comprises oral administration of said composition having a total dosage volume of no greater than 3.0 ml.
10. The method according to claim 9 wherein the composition contacts the mucosal membranes of the mouth.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/974,347 US7138133B2 (en) | 2001-10-10 | 2001-10-10 | Orally administered liquid compositions |
| US09/974,347 | 2001-10-10 | ||
| PCT/US2002/030641 WO2003030877A1 (en) | 2001-10-10 | 2002-09-27 | Orally administered liquid compositions comprising guaifenesin and a polyoxyalkylene block copolymer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2002327744A1 true AU2002327744A1 (en) | 2003-07-03 |
| AU2002327744B2 AU2002327744B2 (en) | 2006-10-12 |
Family
ID=25521922
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2002327744A Ceased AU2002327744B2 (en) | 2001-10-10 | 2002-09-27 | Orally administered liquid compositions comprising guaifenesin and a polyoxyalkylene block copolymer |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US7138133B2 (en) |
| EP (1) | EP1438031B1 (en) |
| JP (1) | JP2005505590A (en) |
| CN (1) | CN1314451C (en) |
| AT (1) | ATE409026T1 (en) |
| AU (1) | AU2002327744B2 (en) |
| BR (1) | BR0213143A (en) |
| CA (1) | CA2462606C (en) |
| DE (1) | DE60229063D1 (en) |
| ES (1) | ES2314089T3 (en) |
| MX (1) | MXPA04003304A (en) |
| PL (1) | PL203209B1 (en) |
| RU (1) | RU2281087C2 (en) |
| WO (1) | WO2003030877A1 (en) |
| ZA (1) | ZA200402046B (en) |
Families Citing this family (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050249802A1 (en) * | 2004-05-06 | 2005-11-10 | The Procter & Gamble Company | Softgel encapsulated pharmaceutical compositions comprising concentrated active ingredients |
| US8758816B2 (en) * | 2004-11-24 | 2014-06-24 | Meda Pharmaceuticals Inc. | Compositions comprising azelastine and methods of use thereof |
| PT2377557T (en) * | 2004-11-24 | 2017-02-07 | Meda Pharmaceuticals Inc | Compositions comprising azelastine and methods of use thereof |
| US20070020330A1 (en) * | 2004-11-24 | 2007-01-25 | Medpointe Healthcare Inc. | Compositions comprising azelastine and methods of use thereof |
| US20090004231A1 (en) | 2007-06-30 | 2009-01-01 | Popp Shane M | Pharmaceutical dosage forms fabricated with nanomaterials for quality monitoring |
| BRPI0819819A2 (en) | 2007-11-21 | 2015-05-26 | Procter & Gamble | Preparations, methods and useful kits for cough treatment |
| US9585973B1 (en) * | 2008-06-05 | 2017-03-07 | Peter Quagliano | Palatable liquid dilution vehicles for oral contrast agents |
| GB2477545B (en) * | 2010-02-05 | 2011-12-21 | Special Products Ltd | A liquid morphine composition for buccal administration |
| DK2593094T3 (en) * | 2010-07-12 | 2018-03-12 | Sanofi Aventis Deutschland | AUTHENTIC COMPOSITION CONTAINING BROMHEXIN |
| AU2011347257A1 (en) | 2010-12-23 | 2013-05-23 | Lectio Pharmaentwicklungs- Und Verwertungs Gmbh | Aqueous solution of ambroxol |
| US9782365B2 (en) | 2011-03-21 | 2017-10-10 | Sanofi-Aventis Deutschland Gmbh | Solid ambroxol-containing preparation |
| AU2012236493A1 (en) | 2011-04-01 | 2013-10-31 | University Of Florida Research Foundation, Inc. | Thermo-sensitive, mucoadhesive or dermoadhesive, and penetration-enhancing formulations for topical delivery of therapeutics |
| US9303038B2 (en) | 2011-09-06 | 2016-04-05 | Cellix Bio Private Limited | Compositions and methods for the treatment of epilepsy and neurological diseases |
| EP2847158A4 (en) | 2012-05-07 | 2015-12-30 | Cellix Bio Private Ltd | Compositions and methods for treatment of neuromuscular disorders and neurodegenerative disorders |
| WO2013167990A1 (en) | 2012-05-07 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of depression |
| CN104350041A (en) | 2012-05-07 | 2015-02-11 | 塞利克斯比奥私人有限公司 | Compositions and methods for the treatment of neurological disorders |
| US9522884B2 (en) | 2012-05-08 | 2016-12-20 | Cellix Bio Private Limited | Compositions and methods for the treatment of metabolic disorders |
| WO2013168023A1 (en) | 2012-05-08 | 2013-11-14 | Mahesh Kandula | Compositions and methods for treatment of parkinson's disease |
| WO2013167988A1 (en) * | 2012-05-08 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of cough |
| WO2013167993A1 (en) | 2012-05-08 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of neurological degenerative disorders |
| US9403826B2 (en) | 2012-05-08 | 2016-08-02 | Cellix Bio Private Limited | Compositions and methods for the treatment of inflammatory disorders |
| WO2013168025A1 (en) | 2012-05-08 | 2013-11-14 | Mahesh Kandula | Compositions and methods for treatment of blood clotting disorders |
| WO2013168002A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of neurological conditions |
| WO2013168015A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of asthma and allergy |
| WO2013168005A2 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of restless leg syndrome and fibromyalgia |
| WO2013168001A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of moderate to severe pain |
| US9346742B2 (en) | 2012-05-10 | 2016-05-24 | Cellix Bio Private Limited | Compositions and methods for the treatment of fibromyalgia pain |
| US9242939B2 (en) | 2012-05-10 | 2016-01-26 | Cellix Bio Private Limited | Compositions and methods for the treatment of respiratory disorders |
| WO2013168011A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of chronic pain |
| WO2013168016A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of metabolic syndrome |
| WO2013168000A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of severe pain |
| WO2013167997A2 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of metabolic syndrome |
| WO2013167999A2 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of neurologic diseases |
| US9499526B2 (en) | 2012-05-10 | 2016-11-22 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurologic diseases |
| US9499527B2 (en) | 2012-05-10 | 2016-11-22 | Cellix Bio Private Limited | Compositions and methods for the treatment of familial amyloid polyneuropathy |
| US9492409B2 (en) | 2012-05-23 | 2016-11-15 | Cellix Bio Private Limited | Compositions and methods for the treatment of local pain |
| US9434729B2 (en) | 2012-05-23 | 2016-09-06 | Cellix Bio Private Limited | Compositions and methods for the treatment of periodontitis and rheumatoid arthritis |
| CA2873098A1 (en) | 2012-05-23 | 2013-11-28 | Cellixbio Private Limited | Compositions and methods for the treatment of multiple sclerosis |
| EP2852570B1 (en) | 2012-05-23 | 2020-04-22 | Cellixbio Private Limited | Composition for the treatment of inflammatory bowel disease |
| US9227974B2 (en) | 2012-05-23 | 2016-01-05 | Cellex Bio Private Limited | Compositions and methods for the treatment of respiratory disorders |
| JP2015518855A (en) | 2012-05-23 | 2015-07-06 | セリックスビオ プライヴェート リミテッド | Compositions and methods for the treatment of mucositis |
| US9108942B1 (en) | 2014-11-05 | 2015-08-18 | Mahesh Kandula | Compositions and methods for the treatment of moderate to severe pain |
| WO2014020480A2 (en) | 2012-08-03 | 2014-02-06 | Mahesh Kandula | Compositions and methods for the treatment migraine and neurologic diseases |
| US9624168B2 (en) | 2012-09-06 | 2017-04-18 | Cellix Bio Private Limited | Compositions and methods for the treatment inflammation and lipid disorders |
| EP2892878A4 (en) | 2012-09-08 | 2016-02-24 | Cellix Bio Private Ltd | Compositions and methods for the treatment of inflammation and lipid disorders |
| US9333187B1 (en) | 2013-05-15 | 2016-05-10 | Cellix Bio Private Limited | Compositions and methods for the treatment of inflammatory bowel disease |
| SG11201509782TA (en) | 2013-06-04 | 2015-12-30 | Cellix Bio Private Ltd | Compositions and methods for the treatment of diabetes and pre-diabetes |
| US9096537B1 (en) | 2014-12-31 | 2015-08-04 | Mahesh Kandula | Compositions and methods for the treatment of mucositis |
| CN104224765B (en) * | 2014-09-03 | 2016-08-24 | 河北仁合益康药业有限公司 | A kind of more phenol bromine new oral administration solution compositions |
| WO2016046835A1 (en) | 2014-09-26 | 2016-03-31 | Cellix Bio Private Limited | Compositions and methods for the treatment of epilepsy and neurological disorders |
| SG11201702554QA (en) | 2014-09-29 | 2017-04-27 | Cellix Bio Private Ltd | Compositions and methods for the treatment of multiple sclerosis |
| EP3212626B1 (en) | 2014-10-27 | 2018-11-07 | Cellix Bio Private Limited | Three component salts of fumaric acid monomethyl ester with piperazine or ethylene diamine for the treatment of multiple sclerosis |
| US9173877B1 (en) | 2014-11-05 | 2015-11-03 | Cellix Bio Private Limited | Compositions and methods for the treatment of local pain |
| US10208014B2 (en) | 2014-11-05 | 2019-02-19 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological disorders |
| US9321716B1 (en) | 2014-11-05 | 2016-04-26 | Cellix Bio Private Limited | Compositions and methods for the treatment of metabolic syndrome |
| US9175008B1 (en) | 2014-11-05 | 2015-11-03 | Cellix Bio Private Limited | Prodrugs of anti-platelet agents |
| US9290486B1 (en) | 2014-11-05 | 2016-03-22 | Cellix Bio Private Limited | Compositions and methods for the treatment of epilepsy |
| US9284287B1 (en) | 2014-11-05 | 2016-03-15 | Cellix Bio Private Limited | Compositions and methods for the suppression of carbonic anhydrase activity |
| US9150557B1 (en) | 2014-11-05 | 2015-10-06 | Cellix Bio Private Limited | Compositions and methods for the treatment of hyperglycemia |
| US9932294B2 (en) | 2014-12-01 | 2018-04-03 | Cellix Bio Private Limited | Compositions and methods for the treatment of multiple sclerosis |
| US9206111B1 (en) | 2014-12-17 | 2015-12-08 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological diseases |
| CN110845355A (en) | 2015-01-06 | 2020-02-28 | 塞尔利克斯生物私人有限公司 | Compositions and methods for treating inflammation and pain |
| US9549907B1 (en) | 2015-11-13 | 2017-01-24 | Sovereign Pharmaceuticals, Llc | Immediate release oral guaifenesin solution |
| EP3544631A1 (en) | 2016-11-28 | 2019-10-02 | Johnson & Johnson Consumer Inc. | Liquid compositions comprising a mucoadhesive agent |
| WO2024005758A1 (en) * | 2022-06-29 | 2024-01-04 | Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi | A stable oral liquid composition comprising terbutaline & guaifenesin |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4188373A (en) * | 1976-02-26 | 1980-02-12 | Cooper Laboratories, Inc. | Clear, water-miscible, liquid pharmaceutical vehicles and compositions which gel at body temperature for drug delivery to mucous membranes |
| US4100271A (en) * | 1976-02-26 | 1978-07-11 | Cooper Laboratories, Inc. | Clear, water-miscible, liquid pharmaceutical vehicles and compositions which gel at body temperature for drug delivery to mucous membranes |
| US4474752A (en) * | 1983-05-16 | 1984-10-02 | Merck & Co., Inc. | Drug delivery system utilizing thermosetting gels |
| US4478822A (en) * | 1983-05-16 | 1984-10-23 | Merck & Co., Inc. | Drug delivery system utilizing thermosetting gels |
| US4474753A (en) * | 1983-05-16 | 1984-10-02 | Merck & Co., Inc. | Topical drug delivery system utilizing thermosetting gels |
| US4511563A (en) * | 1983-07-15 | 1985-04-16 | Basf Wyandotte Corporation | Clear analgesic gels with reduced tackiness |
| IL79552A0 (en) | 1985-07-30 | 1986-10-31 | Int Minerals & Chem Corp | Stabilization of growth promoting hormones |
| DE3532562A1 (en) * | 1985-09-12 | 1987-03-12 | Dolorgiet Gmbh & Co Kg | TRANSDERMALLY RESORBABLE, WATER-BASED PREPARATIONS OF ARYLPROPIONIC ACID DERIVATIVES AND METHOD FOR THE PRODUCTION THEREOF |
| US4673679A (en) * | 1986-05-14 | 1987-06-16 | E. I. Du Pont De Nemours And Company | Use of prodrugs of 3-hydroxymorphinans to prevent bitter taste upon buccal, nasal or sublingual administration |
| US5030448A (en) * | 1986-05-15 | 1991-07-09 | Emory University | Method of delivering drugs to damaged or diseased tissue |
| US5071643A (en) | 1986-10-17 | 1991-12-10 | R. P. Scherer Corporation | Solvent system enhancing the solubility of pharmaceuticals for encapsulation |
| US4810503A (en) * | 1987-03-31 | 1989-03-07 | Basf Corporation | Polymers which form gels at low concentrations in water |
| JP2627158B2 (en) * | 1987-11-20 | 1997-07-02 | ゼリア新薬工業株式会社 | Stable aqueous solution of fat-soluble substance |
| US5135751A (en) | 1988-11-16 | 1992-08-04 | Mediventures Incorporated | Composition for reducing postsurgical adhesions |
| US4911926A (en) | 1988-11-16 | 1990-03-27 | Mediventures Inc. | Method and composition for reducing postsurgical adhesions |
| US5681576A (en) | 1988-11-16 | 1997-10-28 | Mdv Technologies, Inc. | Method and composition for post surgical adhesion reduction |
| CA2011423A1 (en) | 1989-03-07 | 1990-09-07 | Peter M. Taylor | Pharmaceutical compositions useful as drug delivery vehicles and/or as wound dressings |
| US5256396A (en) | 1990-01-24 | 1993-10-26 | Colgate-Palmolive Company | Topical composition |
| US5100898A (en) | 1990-01-25 | 1992-03-31 | Richardson-Vicks Inc. | Antitussive liquid compositions containing dyclonine |
| US5298260A (en) | 1990-05-01 | 1994-03-29 | Mediventures, Inc. | Topical drug delivery with polyoxyalkylene polymer thermoreversible gels adjustable for pH and osmolality |
| US5300295A (en) | 1990-05-01 | 1994-04-05 | Mediventures, Inc. | Ophthalmic drug delivery with thermoreversible polyoxyalkylene gels adjustable for pH |
| US5306501A (en) | 1990-05-01 | 1994-04-26 | Mediventures, Inc. | Drug delivery by injection with thermoreversible gels containing polyoxyalkylene copolymers |
| US5292516A (en) | 1990-05-01 | 1994-03-08 | Mediventures, Inc. | Body cavity drug delivery with thermoreversible gels containing polyoxyalkylene copolymers |
| US5346703A (en) | 1990-08-07 | 1994-09-13 | Mediventures, Inc. | Body cavity drug delivery with thermo-irreversible polyoxyalkylene and ionic polysaccharide gels |
| US5071644A (en) | 1990-08-07 | 1991-12-10 | Mediventures, Inc. | Topical drug delivery with thermo-irreversible gels |
| US5143731A (en) | 1990-08-07 | 1992-09-01 | Mediventures Incorporated | Body cavity drug delivery with thermo-irreversible polyoxyalkylene and ionic polysaccharide gels |
| US5183669A (en) * | 1991-05-28 | 1993-02-02 | Guillemette A Roger | Deflector for crosshead extruder |
| US5141961A (en) | 1991-06-27 | 1992-08-25 | Richrdson-Vicks Inc. | Process for solubilizing difficulty soluble pharmaceutical actives |
| US5318780A (en) | 1991-10-30 | 1994-06-07 | Mediventures Inc. | Medical uses of in situ formed gels |
| EP0551626A1 (en) | 1991-12-19 | 1993-07-21 | LEK, tovarna farmacevtskih in kemicnih izdelkov, d.d. | Thermoreversible gel as a liquid pharmaceutical carrier for a galenic formulation |
| US5505961A (en) | 1993-08-05 | 1996-04-09 | R. P. Scherer Corporation | Gelatin capsules containing a highly concentrated acetaminophen solution |
| CN1106259A (en) | 1994-02-05 | 1995-08-09 | 日东制药株式会社 | Antiphlogistic and analgesic gel agent for external use containing propanoic acid non steroid pharmaceutical as effective composition |
| IT1274026B (en) | 1994-03-01 | 1997-07-14 | Acraf | ANTITOSSE COMPOSITION |
| US5510389A (en) | 1994-03-02 | 1996-04-23 | The Procter & Gamble Company | Concentrated acetaminophen solution compositions |
| KR0163563B1 (en) | 1994-03-23 | 1998-12-01 | 김종인 | Topical drug in combination for treatment of skin lesions |
| JPH11502839A (en) | 1995-03-29 | 1999-03-09 | ザ、プロクター、エンド、ギャンブル、カンパニー | Antitussive microcapsules |
| KR0180334B1 (en) | 1995-09-21 | 1999-03-20 | 김윤 | Drug messenger using el-2l-2 micelle and method for sealing drug to it |
| WO1998029127A1 (en) | 1995-10-06 | 1998-07-09 | Mdv Technologies, Inc. | Method and non-gelling composition for inhibiting post-surgical adhesions |
| DE19545043A1 (en) | 1995-12-02 | 1997-06-05 | Scherer Gmbh R P | Pharmaceutical preparations for oral use and process for their preparation |
| AU1332997A (en) | 1995-12-11 | 1997-07-03 | Mdv Technologies, Inc. | Ophthalmic composition comprising polyoxyethylene-polyoxypropylene polymers |
| ES2234010T3 (en) | 1996-04-12 | 2005-06-16 | Novadel Pharma Inc. | POLAR ORAL SPRAY. |
| US5955098A (en) | 1996-04-12 | 1999-09-21 | Flemington Pharmaceutical Corp. | Buccal non polar spray or capsule |
| US5869082A (en) | 1996-04-12 | 1999-02-09 | Flemington Pharmaceutical Corp. | Buccal, non-polar spray for nitroglycerin |
| SE9601528D0 (en) | 1996-04-23 | 1996-04-23 | Pharmacia Ab | Transdermally administered dextromethorphan as an antitissue agent |
| WO1998006438A2 (en) | 1996-08-12 | 1998-02-19 | Medlogic Global Corporation | Composition for pharmaceutical applications |
| US6290986B1 (en) * | 1996-10-24 | 2001-09-18 | Pharmaceutical Applications Associates, Llc | Method and composition for transdermal administration of pharmacologic agents |
| US5820854A (en) | 1997-03-27 | 1998-10-13 | The Procter & Gamble Company | Oral compositions containing polyoxyethylene |
| EP2042161A1 (en) | 1997-10-01 | 2009-04-01 | Novadel Pharma Inc. | Propellant-free spray composition comprising anti-emetic agent |
| EP1039932A1 (en) | 1997-12-23 | 2000-10-04 | Alliance Pharmaceutical Corporation | Methods and compositions for the delivery of pharmaceutical agents and/or the prevention of adhesions |
| GB9822170D0 (en) | 1998-10-13 | 1998-12-02 | Danbioyst Uk Ltd | Novel formulations of fexofenadine |
| US6846495B2 (en) | 1999-01-11 | 2005-01-25 | The Procter & Gamble Company | Compositions having improved delivery of actives |
| ES2282134T3 (en) | 1999-09-11 | 2007-10-16 | THE PROCTER & GAMBLE COMPANY | POLYOXIALQUYLENE COPOLYMERS CONTAINING FLUID LIQUID VEHICLES. |
| JP2003510279A (en) * | 1999-09-29 | 2003-03-18 | ザ、プロクター、エンド、ギャンブル、カンパニー | Composition with improved stability |
-
2001
- 2001-10-10 US US09/974,347 patent/US7138133B2/en not_active Expired - Fee Related
-
2002
- 2002-09-27 ES ES02763751T patent/ES2314089T3/en not_active Expired - Lifetime
- 2002-09-27 MX MXPA04003304A patent/MXPA04003304A/en active IP Right Grant
- 2002-09-27 BR BR0213143-9A patent/BR0213143A/en not_active Application Discontinuation
- 2002-09-27 RU RU2004114225/15A patent/RU2281087C2/en not_active IP Right Cessation
- 2002-09-27 CA CA002462606A patent/CA2462606C/en not_active Expired - Fee Related
- 2002-09-27 CN CNB028198905A patent/CN1314451C/en not_active Expired - Fee Related
- 2002-09-27 AT AT02763751T patent/ATE409026T1/en not_active IP Right Cessation
- 2002-09-27 JP JP2003533909A patent/JP2005505590A/en active Pending
- 2002-09-27 DE DE60229063T patent/DE60229063D1/en not_active Expired - Lifetime
- 2002-09-27 PL PL370068A patent/PL203209B1/en unknown
- 2002-09-27 WO PCT/US2002/030641 patent/WO2003030877A1/en active Application Filing
- 2002-09-27 AU AU2002327744A patent/AU2002327744B2/en not_active Ceased
- 2002-09-27 EP EP02763751A patent/EP1438031B1/en not_active Expired - Lifetime
-
2004
- 2004-03-15 ZA ZA200402046A patent/ZA200402046B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2462606C (en) | Orally administered liquid compositions comprising guaifenesin and a polyoxyalkylene block copolymer | |
| AU2002327744A1 (en) | Orally administered liquid compositions comprising guaifenesin and a polyoxyalkylene block copolymer | |
| AU2016208390B2 (en) | Enhanced stability of novel liquid compositions | |
| CA2383570C (en) | Pourable liquid vehicles | |
| CZ2002947A3 (en) | Liquid preparation, most preferably oral preparation with enhanced stability and process of its preparation | |
| BRPI0714399A2 (en) | oral liquid pharmaceutical composition, method of treating a mammal in need of treatment; and aqueous, oral pharmaceutical composition | |
| WO2000041692A2 (en) | Compositions having improved stability | |
| EP1321140B1 (en) | Ibuprofen solutions for capsule-filling and capsule preparations | |
| AU771478B2 (en) | Compositions having improved stability | |
| Metkari et al. | Fast dissolving film: Novel drug delivery system | |
| BR112021016408A2 (en) | MINIMIZATION OF AERATION OF SUSPENSIONS DURING IN-LINE MIXING |